Abstract: Provided are a display panel and a display device. The display panel includes a display area including pixel areas, each of which includes at least two sub-pixel areas each including a display light-emitting diode. The sub-pixel areas include shared sub-pixel areas, each of which is shared by at least two pixel areas and includes m spare binding areas, where m?2. The shared sub-pixel areas include a first shared sub-pixel area, in which the display light-emitting diode does not emit light. Each first shared sub-pixel area includes n spare light-emitting diodes, where 2?n?m. When the display panel is driven to emit light, standard brightness required to be displayed by each first shared sub-pixel area is L1 and luminous brightness of each spare light-emitting diode in the first shared sub-pixel area is L2, where L2<L1. The present disclosure can weaken influence on display effect caused by shifting of the light-emitting center.

Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Abstract: A display panel includes a first display area, a second display area, and a transition display area there-between. The first display area includes a plurality of first sub-display areas, the second display area includes a plurality of second sub-display areas, and the transition display area includes at least one sub-transition area. A first sub-display area of the plurality of first sub-display areas, a second sub-display area of the plurality of second sub-display areas and a sub-transition area include a same number of light-emitting elements. Number of pixel circuits for driving each light-emitting element in one of the at least one sub-transition area is greater than number of pixel circuits for driving each light-emitting element in one of the plurality of first sub-display areas and is smaller than number of pixel circuits for driving each light-emitting element in one of the plurality of second sub-display areas.

Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Abstract: A driving substrate and a display panel are provided. The driving substrate includes driving modules. Each of the driving modules includes two electrodes. Each of at least one of the two electrodes includes convex parts, and each of the convex parts protrudes from one of the two electrodes where the convex parts are located towards the other one of the two electrodes.

Abstract: A light-emitting diode (LED) display panel and a display device are provided. The LED display panel includes a substrate, an array layer at a side of the substrate, and a light-emitting device at a side of the array layer away from the substrate. The array layer includes an insulating layer and a driving device; the insulating layer includes a groove; the groove is between an edge of the display panel and the driving device; and/or the groove is between the light-emitting device and the driving device.

Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

Abstract: Provided are a display panel and a display device. The display panel includes a pixel circuit and a light-emitting element. In the pixel circuit, the gate of a drive transistor is connected to a first node, a reset module includes a first transistor. One end of the first transistor is connected to the first node, and another end is connected to a second node. A compensation module includes a second transistor and a third transistor. The connection node between the second transistor and the third transistor is a third node. Another end of the second transistor is connected to the first node. In one refresh frame, the first transistor and the second transistor are off in a first stage, and a voltage V1 of the first node, a voltage V2 of the second node and a voltage V3 of the third node satisfy V1?V2=K(V3?V2).

Abstract: Provided are display panel and display device. Display panel includes base substrate; light-emitting element located on base substrate; first electrode and second electrode both electrically connected to light-emitting element, both located on side of light-emitting element facing base substrate or on side of light-emitting element facing away from base substrate and both providing voltage signals for light-emitting element; first reflective layer located on side of light-emitting element facing base substrate, and with direction perpendicular to base substrate as projection direction, first reflective layer covering light-emitting element; and voltage signal line located on side of light-emitting element facing base substrate. First electrode and second electrode respectively include first extension part and second extension part, at least one of which is connected to voltage signal line and does not overlap first reflective layer.

Abstract: A driving substrate and a display panel are provided. The driving substrate includes driving modules. Each of the driving modules includes two electrodes. Each of at least one of the two electrodes includes convex parts, and each of the convex parts protrudes from one of the two electrodes where the convex parts are located towards the other one of the two electrodes.

Abstract: Provided are a display panel and a display device. The display panel includes a first display area and a second display area. The first display area is reused as a sensor reserved area. The first display area includes a plurality of first pixel units. The second display area includes a plurality of second pixel units. The plurality of first pixel units include micro light-emitting diode pixel units, and the plurality of second pixel units include organic light-emitting diode pixel units. The first display area at least includes a region in which density of the plurality of first pixel units in the first display area is configured to be gradually decreased along a first direction.

Abstract: Provided are a display panel and a display device. The display panel includes a display area including pixel areas, each of which includes at least two sub-pixel areas each including a display light-emitting diode. The sub-pixel areas include shared sub-pixel areas, each of which is shared by at least two pixel areas and includes m spare binding areas, where m?2. The shared sub-pixel areas include a first shared sub-pixel area, in which the display light-emitting diode does not emit light. Each first shared sub-pixel area includes n spare light-emitting diodes, where 2?n?m. When the display panel is driven to emit light, standard brightness required to be displayed by each first shared sub-pixel area is L and luminous brightness of each spare light-emitting diode in the first shared sub-pixel area is L2, where L2<L1. The present disclosure can weaken influence on display effect caused by shifting of the light-emitting center.

Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Abstract: A display panel, a method for manufacturing the display panel, and a display device including the display panel are provided. The display panel includes: a thin film transistor array layer, and a light-emitting function layer at a side of the thin film transistor array layer. The thin film transistor array layer includes a planarization layer, an electrode layer, a first insulation layer, an active layer and a buffer layer. The electrode layer includes at least one first electrode and second electrode, and each first electrode includes a connection portion and an electrode portion which are connected to each other. The light-emitting function layer includes first contact electrodes and light-emitting elements. Heat generated by the light-emitting function layer is conducted to electrode portion of the first electrode through the connection portion of the first electrode and is uniformly distributed on the connection portion and the electrode portion.

Abstract: Provided are a display panel and a display device. The display panel includes a first display area and a second display area. The first display area is reused as a sensor reserved area. The first display area includes a plurality of first pixel units. The second display area includes a plurality of second pixel units. The plurality of first pixel units include micro light-emitting diode pixel units, and the plurality of second pixel units include organic light-emitting diode pixel units. The first display area at least includes a region in which density of the plurality of first pixel units in the first display area is configured to be gradually decreased along a first direction.

Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.